AZNAstraZenecaRunning, no new patients
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 127 (final count)
- Started
- Feb 22, 2024
- Main results expected
- Feb 10, 2027
- Fully finished
- Feb 10, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (ORR)
Measured over: An average of approximately 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06271837 · record last updated 2026-09-03 · checked 2026-11-09 15:47 UTC